Aptevo Therapeutics Inc. Common Stock (APVO)

About APVO

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

33

Website

aptevotherapeutics.com/

Fundamentals

1-day range

$2.32$2.46

Market cap

$6.18M

P/E (trailing)

0.00

P/E (forward)

-0.23

EPS (trailing)

$-197.29

Dividend yield

—

Beta

1.71

Avg. volume

56.9K

Dividend pay date

March 27, 2020

Forecasts

2 analyst ratings

Aptevo Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• APVO

  Aptevo Therapeutics Inc. Common Stock

  $2.36

  ▼ 2.48%
  Market cap $6.18MP/E 0.00
  $2.3$48.78
• HCWB

  HCW Biologics Inc. Common Stock

  $3.39

  ▲ 6.94%
  Market cap $6.19MP/E —
  $1.5$38.16
• ACXP

  Acurx Pharmaceuticals Inc. Common Stock

  $1.45

  ▼ 1.03%
  Market cap $6.27MP/E —
  $1.31$8.34
• PULM

  Pulmatrix Inc. Common Stock

  $1.51

  ▼ 0.66%
  Market cap $6.06MP/E —
  $1.16$5.5
• XBIO

  Xenetic Biosciences Inc. Common Stock

  $3.98

  ▲ 1.66%
  Market cap $6.53MP/E —
• ALZN

  Alzamend Neuro Inc. Common Stock

  $1.66

  ▼ 0.30%
  Market cap $6.61MP/E —
  $0.84$2.68
• IMNN

  Imunon Inc. Common Stock

  $1.58

  ▼ 1.25%
  Market cap $6.64MP/E —
  $1.47$6.39

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Watching Aptevo Therapeutics; Zacks Small-Cap Research Gives Stock $30 Price Valuation
  benzinga · 8/24/2026
• Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
  Yahoo · 8/14/2026
• Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate
  Benzinga · 8/14/2026
• Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
  Yahoo · 8/13/2026
• Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE
  Benzinga · 8/13/2026
• Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
  Yahoo · 8/12/2026

• Jeffrey G. Lamothe · August 6, 2026 · Option Exercise

  961
• SoYoung Kwon · August 6, 2026 · Option Exercise

  638
• Dirk Huebner · August 6, 2026 · Option Exercise

  638
• Dirk Huebner · August 6, 2026 · Tax Withholding

  156 @ $4.07
• Grady Grant III · August 6, 2026 · Option Exercise

  400
• Barbara Lopez Kunz · August 6, 2026 · Option Exercise

  400
• John Niederhuber · August 6, 2026 · Option Exercise

  400
• Marvin L. White · August 6, 2026 · Option Exercise

  1.7K
• Marvin L. White · August 6, 2026 · Tax Withholding

  406 @ $4.07
• Daphne Taylor · August 6, 2026 · Option Exercise

  638
• Daniel Abdun-Nabi · August 6, 2026 · Option Exercise

  400
• Zsolt Harsanyi · August 6, 2026 · Option Exercise

  400
• Marvin L. White · July 17, 2026 · Option Exercise

  1

Institutional Ownership

March 31, 2026

Total shares held

49.6K

Total value held

$128.1K

Institutional holders

8